Latest news

• EMA grants AZ’s Vaxzevria COVID-19 vaccine full marketing authorisation

  third dose booster.

• Novavax’s COVID-19 vaccine candidate approved for emergency use by FDA as a booster

  The authorisation is for those unable to receive an FDA-authorised mRNA bivalent booster. ... In the COV-BOOST trial, the booster induced a ‘robust antibody response’ when used as a heterologous third booster dose.

• Novavax’s COVID-19 vaccine candidate receives EC approval for use as a booster

  Nuvaxovid induced a ‘robust antibody response’ when used as a heterologous third booster dose. ... In the COV-BOOST trial, Nuvaxovid induced a ‘robust antibody response’ when used as a heterologous third booster dose.

• Novavax’s COVID-19 vaccine candidate receives CHMP recommendation for use as a booster

  The protein-based vaccine induced a ‘robust antibody response’ when used as a heterologous third booster dose, data from a UK-sponsored trial showed. ... In the COV-BOOST trial, Nuvaxovid induced a ‘robust antibody response’ when used as a

• AstraZeneca’s COVID-19 vaccine receives EMA approval for use as third-dose booster

  AstraZeneca has received approval from the European Medicine Agency (EMA) for its COVID-19 vaccine, Vaxzevria, to be used as a third-dose booster to protect adults against the virus. ... The EMA based its decision on a review conducted by the Committee